Association of Other Autoimmune Diseases With Thyroid Eye Disease.
Adult
Arthritis, Rheumatoid
/ complications
Autoimmune Diseases
/ complications
Autoimmunity
Female
Graves Ophthalmopathy
/ complications
Hospitals
Humans
Immunosuppression Therapy
London
Male
Middle Aged
Psoriasis
/ complications
Retrospective Studies
Severity of Illness Index
Surveys and Questionnaires
Treatment Outcome
United Kingdom
clinical activity score
disease severity
ethnically diverse
immunosuppression
polyautoimmunity
psoriasis
rheumatoid arthritis
thyroid eye disease
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2021
2021
Historique:
received:
20
12
2020
accepted:
26
01
2021
entrez:
22
3
2021
pubmed:
23
3
2021
medline:
15
1
2022
Statut:
epublish
Résumé
Thyroid eye disease (TED) is a potentially disfiguring and sight-threatening autoimmune (AI) orbitopathy, affecting up to 400,000 people in the UK. There are no accurate early predictors of TED severity. Although polyautoimmunity has been shown to affect AI disease severity, its influence on TED severity has never been investigated. The prevalence of polyautoimmunity among TED patients is also unclear, with discordant results reported in the literature. This study evaluates the prevalence of non-thyroid/"other" AI (OAI) conditions in an ethnically diverse TED cohort and assesses how polyautoimmunity affects TED severity and activity. A retrospective study of patients presenting to multidisciplinary TED clinics across three North-West London hospitals between 2011 and 2019. Data collected included: 1) demographics; 2) OAI conditions and management; 3) endocrine management of thyroid dysfunction; 4) details of TED and clinical activity score at presentation. Two hundred and sixty-seven patients with a median age of 46 (35-54) years were included, 79.4% were female and 55% were Black, Asian and minority ethnic (BAME). Thirty-seven patients (13.9%) had OAI conditions, with rheumatoid arthritis (3.7%), vitiligo (3.0%) and psoriasis (3.0%) among the most prevalent. Of patients with OAI conditions, 43.2% (16/37) required immunosuppression prior to TED onset. Non-immunosuppressed patients with OAI conditions had a significantly higher clinical activity score at presentation than TED-only and previously immunosuppressed patients (p=0.02). No significant differences were observed in thyroid receptor antibody titers between these groups. This study finds a 13.9% prevalence of OAI conditions among TED patients. Patients with OAI conditions overall have a tendency for more severe and significantly more clinically active TED than those without OAI conditions. Larger, prospective studies are warranted to further evaluate polyautoimmunity as an early predictor of TED severity.
Sections du résumé
Background
Thyroid eye disease (TED) is a potentially disfiguring and sight-threatening autoimmune (AI) orbitopathy, affecting up to 400,000 people in the UK. There are no accurate early predictors of TED severity. Although polyautoimmunity has been shown to affect AI disease severity, its influence on TED severity has never been investigated. The prevalence of polyautoimmunity among TED patients is also unclear, with discordant results reported in the literature. This study evaluates the prevalence of non-thyroid/"other" AI (OAI) conditions in an ethnically diverse TED cohort and assesses how polyautoimmunity affects TED severity and activity.
Methods
A retrospective study of patients presenting to multidisciplinary TED clinics across three North-West London hospitals between 2011 and 2019. Data collected included: 1) demographics; 2) OAI conditions and management; 3) endocrine management of thyroid dysfunction; 4) details of TED and clinical activity score at presentation.
Results
Two hundred and sixty-seven patients with a median age of 46 (35-54) years were included, 79.4% were female and 55% were Black, Asian and minority ethnic (BAME). Thirty-seven patients (13.9%) had OAI conditions, with rheumatoid arthritis (3.7%), vitiligo (3.0%) and psoriasis (3.0%) among the most prevalent. Of patients with OAI conditions, 43.2% (16/37) required immunosuppression prior to TED onset. Non-immunosuppressed patients with OAI conditions had a significantly higher clinical activity score at presentation than TED-only and previously immunosuppressed patients (p=0.02). No significant differences were observed in thyroid receptor antibody titers between these groups.
Conclusions
This study finds a 13.9% prevalence of OAI conditions among TED patients. Patients with OAI conditions overall have a tendency for more severe and significantly more clinically active TED than those without OAI conditions. Larger, prospective studies are warranted to further evaluate polyautoimmunity as an early predictor of TED severity.
Identifiants
pubmed: 33746907
doi: 10.3389/fendo.2021.644200
pmc: PMC7973359
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
644200Informations de copyright
Copyright © 2021 Kelada, Avari, Farag, Akishar, Jain, Aziz, Feeney, Bravis, Meeran and Lee.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Autoimmunity. 2009 Feb;42(2):126-30
pubmed: 19021011
Br J Ophthalmol. 2004 Jan;88(1):75-8
pubmed: 14693779
J Endocrinol Invest. 2020 Aug;43(8):1149-1151
pubmed: 32441005
Medicine (Baltimore). 2006 Mar;85(2):95-104
pubmed: 16609348
J Dtsch Dermatol Ges. 2020 Aug;18(8):795-807
pubmed: 32761894
Eye (Lond). 2019 Feb;33(2):223-229
pubmed: 30498266
J Fr Ophtalmol. 1994;17(5):331-8
pubmed: 8089419
J Clin Endocrinol Metab. 2008 Mar;93(3):1077-81
pubmed: 18073300
Ann Rheum Dis. 2008 Feb;67(2):248-50
pubmed: 17606463
J Rheumatol. 2010 Mar;37(3):608-14
pubmed: 20110522
J Clin Endocrinol Metab. 1997 Feb;82(2):438-43
pubmed: 9024233
J Clin Endocrinol Metab. 2013 Jan;98(1):145-52
pubmed: 23185037
Neuropsychobiology. 1982;8(6):289-96
pubmed: 7162583
J Am Acad Dermatol. 2016 Feb;74(2):295-302
pubmed: 26518171
Orbit. 2017 Jun;36(3):159-169
pubmed: 28296512
Dermatology. 2013;227(4):311-5
pubmed: 24107643
F1000Res. 2017 Sep 28;6:1776
pubmed: 29043075
Autoimmune Dis. 2012;2012:254319
pubmed: 22454759
Best Pract Res Clin Endocrinol Metab. 2012 Jun;26(3):273-9
pubmed: 22632364
Ophthalmology. 1996 Jun;103(6):958-62
pubmed: 8643255
Eye Vis (Lond). 2014 Dec 10;1:9
pubmed: 26605355
Rev Endocr Metab Disord. 2018 Dec;19(4):363-395
pubmed: 30673921
Am J Hum Genet. 2007 Feb;80(2):273-90
pubmed: 17236132
Thyroid. 2020 Mar;30(3):457-462
pubmed: 31910128
Thyroid. 2015 Mar;25(3):347-51
pubmed: 25584927
Ophthalmic Plast Reconstr Surg. 2007 Mar-Apr;23(2):104-8
pubmed: 17413622
Acta Neurol Scand. 1995 Mar;91(3):192-5
pubmed: 7793234
Autoimmun Rev. 2019 Mar;18(3):287-292
pubmed: 30639646
Br Med Bull. 2011;99:39-51
pubmed: 21893493
Br J Dermatol. 2013 Apr;168(4):756-61
pubmed: 23253044
Science. 2006 Dec 1;314(5804):1461-3
pubmed: 17068223
Rheumatology (Oxford). 2002 Jul;41(7):793-800
pubmed: 12096230